Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.06.2023 | Case report

Dapagliflozin/empagliflozin

Renal impairment and urinary tract infection: 2 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Yang A-Y, et al. Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes. Journal of Diabetes Research 2022: 23 May 2022. Available from: URL: http://doi.org/10.1155/2022/2420857 Yang A-Y, et al. Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes. Journal of Diabetes Research 2022: 23 May 2022. Available from: URL: http://​doi.​org/​10.​1155/​2022/​2420857
Metadaten
Titel
Dapagliflozin/empagliflozin
Renal impairment and urinary tract infection: 2 case reports
Publikationsdatum
01.06.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-41403-y

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Covid-19-vaccine

Case report

Azd-1222

Case report

Thiotepa